Showing 1101-1110 of 1211 results for "".
- Rabb-Venable Excellence in Ophthalmology Program Abstract Submission Open Until March 31https://modernod.com/news/rabb-venable-excellence-in-ophthalmology-program-abstract-submission-open-until-march-31/2478981/Each year, the National Medical Association–Ophthalmology Section sponsors the Rabb-Venable Excellence in Ophthalmology Program, which is committed to increasing diversity in eye care to better reflect the U.S. population. The Rabb-Venable Program encourages and fosters interest in ophthal
- New Study Links Protein Causing Alzheimer’s Disease With Common Sight Losshttps://modernod.com/news/new-study-links-protein-causing-alzheimers-disease-with-common-sight-loss/2478957/Newly published research has revealed a close link between proteins associated with Alzheimer’s disease and age-related sight loss. The findings could open the way to new treatments for patients with deteriorating vision and through this study, scientists believe they could reduce the need for us
- Glaukos to Support World Glaucoma Week with Patient Education Campaign and Free Screening Initiativeshttps://modernod.com/news/glaukos-to-support-world-glaucoma-week-with-patient-education-campaign-and-free-screening-initiatives/2478945/Glaukos announced two new patient-centric initiatives in honor of World Glaucoma Week. World Glaucoma Week is an annual global initiative championed by the World Glaucoma Association (WGA) to raise awareness surrounding the risk and prevalence of glaucoma. As a sponsor of the WGA, Glaukos is laun
- International Team Identifies 127 Glaucoma Genes in Largest Study of Its Kindhttps://modernod.com/news/international-team-identifies-127-glaucoma-genes-in-largest-study-of-its-kind/2478911/In the largest genome-wide association study of glaucoma comparing the genes of 34,179 people with the disease to 349,321 control subjects, an international consortium of researchers identified 44 new gene loci and confirmed 83 previously reported loci linked to glaucoma, according to a Massachus
- Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (Perfluorohexyloctane)https://modernod.com/news/bausch-lomb-completes-enrollment-of-first-phase-3-study-for-nov03-perfluorohexyloctane/2478770/Bausch + Lomb and Novaliq announced the first of two phase 3 studies evaluating NOV03 as a first-in-class investigational drug with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD) has been completely enrolled w
- Neurophth and AAVnerGene Enter Strategic Partnership for Next-Generation Ophthalmic Gene Therapyhttps://modernod.com/news/neurophth-and-aavnergene-enter-strategic-partnership-for-next-generation-ophthalmic-gene-therapy/2478771/Neurophth Therapeutics, a subsidiary of Wuhan Neurophth Biotechnology gene therapy company, and AAVnerGene, an AAV technology company, announced a strategic partnership to provide Neurophth with worldwide rights to mutually select adeno-associated virus (AAV) capsids for the next generation ophth
- CVP Welcomes Three New Ophthalmology Partner Practiceshttps://modernod.com/news/cvp-welcomes-three-new-ophthalmology-partner-practices/2478760/CVP has expanded its platform in the Midwest and Mid-Atlantic regions by adding three partner practices: Columbus Ophthalmology Associates (COA), Valley Eye Institute, near Dayton, Ohio; and Virginia Beach Eye Center. CVP now includes a network of nine partner pra
- Allergan Announces Positive Phase 3 Topline Results for Investigational Eye Drop for the Treatment of Presbyopiahttps://modernod.com/news/allergan-announces-positive-phase-3-topline-results-for-investigational-eye-drop-for-the-treatment-of-presbyopia/2478467/Allergan announced the phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety, and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with presbyopia, met their primary efficacy endpoint. In GEMINI 1,
- AstraZeneca’s COVID-19 Vaccine Produces Robust Immune Response in Elderlyhttps://modernod.com/news/astrazenecas-covid-19-vaccine-produces-robust-immune-response-in-elderly/2478462/AstraZeneca disclosed that its experimental COVID-19 vaccine AZD1222 triggered a robust immune response in elderly and older adults, similar to that previously seen in healthy study volunteers aged between 18 and 55. Adverse events associated with the vaccine, which is being co-developed with the
- Allergan Announces Updates to Eye Care Optometric Professional Relations Teamhttps://modernod.com/news/allergan-announces-updates-to-eye-care-optometric-professional-relations-team/2478432/Allergan Eye Care announced the retirement of Dave Gibson, Associate VP of Consumer Eye Care and Customer Development, after 20 years of service. Since 2009, Mr. Gibson has led Allergan’s Optometric Professional Relations team and helped launch a variety of programs to support the optometry com